Advanced Group, founded by Indian entrepreneur Rajesh Sharma, has entered the design phase for a new pharmaceutical manufacturing facility at the Dubna Special Economic Zone (SEZ). The project, valued at over 2.5 billion rubles, aims to localize the production of critically important medicines, including oncology and HIV treatments.
The large-scale production and warehouse complex, spanning 24,000 square meters, will be constructed on the 4th stage of the SEZ’s left-bank site. On a 4-hectare plot, the resident plans to deploy three specialized units focused on the production of finished dosage forms (FDF), anti-tumor medications, and biotechnological products. Как PHARMPROM previously reported, the company is consistently executing its strategy to substitute vital drug imports. The project is expected to create at least 300 high-tech jobs.
Strategic Importance for the Region
The new facility will become the second major Indian-capital pharmaceutical asset in this location following PSK Pharma, strengthening the Moscow region’s position as a key hub for the Russian-Indian partnership in Life Sciences.
“Advanced plans to invest over 2.5 billion rubles in the project. At the SEZ site, the new resident intends to develop and manufacture medicines for the treatment of socially significant diseases, including oncology drugs, antibacterial and anti-tuberculosis agents, as well as medications for HIV infection, diabetes, and cardiovascular diseases.”
— Ekaterina Zinovieva, Deputy Prime Minister – Minister of Investment, Industry, and Science of the Moscow Region
Expertise and Technological Base
Advanced Group has been present in the Russian market for over 20 years. The accumulated expertise in modernizing facilities in the Perm and Belgorod regions will be utilized to establish this new full-cycle plant.
“Advanced Group has been operating in the Russian pharmaceutical market since 2003. Its portfolio includes successfully implemented projects for the modernization and creation of new production facilities in the Perm and Belgorod regions, as well as the development of export relations with the Republic of Uzbekistan, where a separate division has been established and is successfully growing. The accumulated experience and competencies will allow us to further expand the portfolio of medicines in high demand in Russia and other countries, including those produced at the Dubna SEZ.”
— Vladimir Kotovich, Development Director of Advanced Group
Implementation Phases and Infrastructure
In 2026, the company intends to complete design works and begin the construction of the first phase of production and engineering facilities. In addition to the manufacturing units, the complex will include a modern warehouse for raw materials and finished products, as well as an autonomous engineering systems hub.
“The Advanced Dubna project holds strategic significance for the Moscow region. Its implementation will allow the region to take a leading position in the federal rating by volume of high-tech modern medicines produced, create conditions for import substitution, and guarantee the fulfillment of regional obligations to provide citizens with high-quality treatment.”
— Anton Afanasiev, Director General of JSC SEZ TVT Dubna
| Parameter | Project Specification |
|---|---|
| Total Investment | Over 2.5 billion rubles |
| Total Complex Area | 24,000 sq. meters |
| Key Therapeutic Areas | Oncology, HIV, Diabetes, Biotech |
| Jobs Created | 300 high-tech positions |
| Investment Cycle | 6 years |
